Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 2, 2025, the company has repurchased a total of 1,492,744 ordinary fully paid securities, including 175,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, providing pathology services. The company focuses on delivering diagnostic services and is listed on the Australian Securities Exchange under the code ACL.
Average Trading Volume: 775,027
Technical Sentiment Signal: Buy
Current Market Cap: A$569.5M
See more insights into ACL stock on TipRanks’ Stock Analysis page.